Fujifilm Diosynth Biotechnologies to produce Argenx antibody

Argenx has contracted the CDMO to make efgartigimod, a monoclonal antibody fragment, at its facility in Hillerød, Denmark.

Photo: Liselotte Plenov / Fotorummet / PR

On Thursday, Fujifilm Diosynth Biotechnologies, a contract manufacturer, or CDMO, entered a deal with Argenx regarding monoclonal antibody fragment efgartigimod, a press release announced.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs